We propose to perform a randomized phase II clinical trial in patients with oligometastatic non-small-cell lung cancer (NSCLC). NSCLC patients are eligible for this clinical trial when failed to respond or progress on anti-PD-1 therapy (pembrolizumab, with or without cytotoxic chemotherapy).
|Effective start/end date||1/10/19 → 30/09/23|
Flemish discipline codes
- Clinical trials